Guardant Health Inc - Understand $gh stock

$GH Market Cap: $3.087 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$643.8M

TTM

Gross Margin

59.95%

TTM

Net Earnings

-$490.8M

TTM

Current Assets

$1.290B

Q2 2024

Current Liabilities

$201.6M

Q2 2024

Current Ratio

639.97%

Q2 2024

Total Assets

$1.609B

Q2 2024

Total Liabilities

$1.611B

Q2 2024

Book Value

-$1.613M

Q2 2024

Cash

$933.7M

Q2 2024

P/E

-6.290

Sep 17, 2024 EST

Free Cash Flow

-$299.3M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$563.9M	$449.5M	$373.7M	$286.7M	$214.4M	$90.64M	$49.84M	$25.25M
YoY Change	25.45%	20.31%	30.32%	33.75%	136.52%	81.85%	97.4%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$563.9M	$449.5M	$373.7M	$286.7M	$214.4M	$90.64M	$49.84M	$25.25M
Cost Of Revenue	$227.1M	$155.6M	$122.2M	$92.50M	$70.70M	$43.20M	$31.60M	$22.10M
Gross Profit	$336.9M	$293.9M	$251.4M	$194.2M	$143.7M	$47.40M	$18.20M	$3.100M
Gross Profit Margin	59.74%	65.38%	67.29%	67.73%	67.03%	52.3%	36.52%	12.28%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Selling, General & Admin	$451.0M	$463.8M	$398.5M	$299.3M	$139.7M	$89.66M	$69.27M	$36.11M
YoY Change	-2.75%	16.38%	33.16%	114.18%	55.85%	29.42%	91.83%
% of Gross Profit	133.88%	157.8%	158.49%	154.11%	97.24%	189.15%	380.63%	1164.94%
Research & Development	$367.2M	$373.8M	$263.2M	$149.9M	$86.29M	$50.71M	$25.56M	$10.86M
YoY Change	-1.77%	42.01%	75.64%	73.67%	70.15%	98.4%	135.4%
% of Gross Profit	108.99%	127.18%	104.68%	77.17%	60.05%	106.99%	140.45%	350.29%
Depreciation & Amortization	$42.88M	$35.96M	$22.27M	$16.07M	$11.41M	$7.136M	$5.206M	$3.693M
YoY Change	19.24%	61.47%	38.63%	40.79%	59.91%	37.07%	40.97%
% of Gross Profit	12.73%	12.24%	8.86%	8.27%	7.94%	15.05%	28.6%	119.13%
Operating Expenses	$818.2M	$837.6M	$661.7M	$449.1M	$226.0M	$140.4M	$94.84M	$46.97M
YoY Change	-2.31%	26.57%	47.33%	98.71%	61.02%	48.01%	101.9%
Operating Profit	-$564.7M	-$544.4M	-$411.0M	-$255.0M	-$82.37M	-$92.94M	-$76.61M	-$43.85M
YoY Change	3.74%	32.45%	61.21%	209.51%	-11.37%	21.32%	74.73%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Interest Expense	$2.578M	$2.577M	$2.577M	$4.766M	$1.181M	$1.251M	$2.702M	$3.018M
YoY Change	0.04%	0.0%	-45.93%	303.56%	-5.6%	-53.7%	-10.47%
% of Operating Profit
Other Income/Expense, Net	$53.17M	-$12.78M	$25.18M	$3.641M	$88.00K	$4.702M	-$1.059M	-$1.000K
YoY Change	-516.14%	-150.75%	591.51%	4037.5%	-98.13%	-544.0%	105800.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Pretax Income	-$478.8M	-$653.4M	-$384.5M	-$245.9M	-$69.72M	-$84.23M	-$83.21M	-$46.13M
YoY Change	-26.73%	69.96%	56.35%	252.69%	-17.22%	1.21%	80.38%
Income Tax	$685.0K	$1.139M	$300.0K	$379.0K	-$1.872M	$38.00K	$7.000K	$6.000K
% Of Pretax Income
Net Earnings	-$479.4M	-$654.6M	-$384.8M	-$246.3M	-$75.65M	-$85.06M	-$83.22M	-$46.14M
YoY Change	-26.76%	70.12%	56.23%	225.55%	-11.06%	2.21%	80.37%
Net Earnings / Revenue	-85.02%	-145.61%	-102.98%	-85.89%	-35.29%	-93.85%	-166.97%	-182.74%
Basic Earnings Per Share	-$4.28	-$6.41	-$4.00	-$2.60	-$0.84
Diluted Earnings Per Share	-$4.28	-$6.41	-$4.00	-$2.60	-$0.84	-$991.8K	-$995.2K	-$551.4K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Short-Term Investments	$1.169B	$1.011B	$932.7M	$1.795B	$522.8M	$419.0M	$221.3M	$95.30M
YoY Change	15.57%	8.41%	-48.03%	243.32%	24.77%	89.34%	132.21%
Cash & Equivalents	$1.134B	$141.6M	$492.2M	$833.0M	$143.2M	$140.5M	$72.30M	$33.60M
Short-Term Investments	$35.10M	$869.6M	$440.5M	$961.9M	$379.6M	$278.4M	$149.0M	$61.70M
Other Short-Term Assets	$27.74M	$31.51M	$53.05M	$17.50M	$11.40M	$5.200M	$1.500M	$1.600M
YoY Change	-11.96%	-40.61%	203.15%	53.51%	119.23%	246.67%	-6.25%
Inventory	$61.95M	$51.60M	$30.67M	$22.70M	$15.20M	$9.100M	$7.300M	$2.800M
Prepaid Expenses
Receivables	$88.78M	$97.26M	$97.65M	$53.30M	$48.00M	$35.70M	$12.80M	$3.500M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.347B	$1.192B	$1.114B	$1.888B	$597.4M	$469.0M	$242.9M	$103.1M
YoY Change	13.05%	6.95%	-41.0%	216.1%	27.38%	93.08%	135.6%
Property, Plant & Equipment	$302.7M	$341.9M	$313.9M	$100.1M	$72.80M	$31.00M	$16.00M	$12.60M
YoY Change	-11.47%	8.93%	213.59%	37.5%	134.84%	93.75%	26.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$698.0M	$246.6M	$268.8M	$77.60M	$73.30M	$0.00
YoY Change		-100.0%	183.06%	-8.26%	246.39%	5.87%
Other Assets	$124.3M	$61.45M	$60.94M	$17.30M	$11.80M	$9.800M	$10.70M	$800.0K
YoY Change	102.32%	0.85%	252.24%	46.61%	20.41%	-8.41%	1237.5%
Total Long-Term Assets	$439.3M	$418.4M	$1.090B	$383.4M	$365.1M	$118.4M	$100.0M	$13.50M
YoY Change	5.0%	-61.63%	184.4%	5.01%	208.36%	18.4%	640.74%
Total Assets	$1.786B	$1.610B	$2.204B	$2.272B	$962.5M	$587.4M	$342.9M	$116.6M
YoY Change
Accounts Payable	$51.74M	$68.91M	$17.58M	$7.300M	$16.20M	$10.60M	$5.000M	$3.200M
YoY Change	-24.92%	291.99%	140.82%	-54.94%	52.83%	112.0%	56.25%
Accrued Expenses	$136.2M	$106.9M	$83.56M	$46.30M	$41.20M	$18.60M	$10.40M	$4.000M
YoY Change	27.41%	27.94%	80.47%	12.38%	121.51%	78.85%	160.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due						$100.0K	$200.0K	$100.0K
YoY Change						-50.0%	100.0%
Total Short-Term Liabilities	$205.9M	$193.2M	$194.7M	$66.80M	$72.70M	$46.90M	$19.60M	$14.30M
YoY Change	6.57%	-0.75%	191.45%	-8.12%	55.01%	139.29%	37.06%
Long-Term Debt	$1.140B	$1.137B	$1.135B	$806.3M	$0.00	$100.0K	$500.0K	$16.90M
YoY Change	0.23%	0.23%	40.74%		-100.0%	-80.0%	-97.04%
Other Long-Term Liabilities	$281.9M	$219.2M	$230.0M	$43.10M	$41.80M	$15.40M	$14.20M	$5.700M
YoY Change	28.59%	-4.69%	433.61%	3.11%	171.43%	8.45%	149.12%
Total Long-Term Liabilities	$1.422B	$1.357B	$1.365B	$849.4M	$41.80M	$15.50M	$14.70M	$22.60M
YoY Change	4.81%	-0.6%	60.68%	1932.06%	169.68%	5.44%	-34.96%
Total Liabilities	$1.628B	$1.550B	$1.559B	$973.3M	$164.1M	$104.3M	$34.30M	$36.90M
YoY Change	5.03%	-0.62%	60.23%	493.11%	57.33%	204.08%	-7.05%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	112.0M shares	102.2M shares	101.3M shares	97.50M shares	90.60M shares
Diluted Shares Outstanding	112.0M shares	102.2M shares	101.3M shares	97.50M shares	90.60M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $3.0866 Billion

About Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,779 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Industry: Services-Medical Laboratories Peers: AMN Healthcare Services Inc Option Care Health Inc Chemed Corp CVS Health Corp LHC Group, Inc MSP Recovery, Inc. Oak Street Health, Inc. Privia Health Group Inc Premier Inc Signify Health, Inc.